Highlights | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Navigation Landing]
Views 1,037
Citations 0
In This Issue of JAMA Internal Medicine
February 2017


JAMA Intern Med. 2017;177(2):151-153. doi:10.1001/jamainternmed.2016.6129

The FAVOURED trial (Fish Oils and Aspirin in Vascular Access Outcomes in Renal Disease) is the first randomized clinical trial to determine whether fish oil or low-dose aspirin is effective in preventing failure of de novo arteriovenous fistulae (AVF) in patients requiring hemodialysis. In this trial that included 567 adults, the occurrence of fistula failure within 12 months of surgery was high (47%) and not reduced by fish oil (relative risk 1.03) or aspirin (relative risk 1.05) compared with placebo. Based on these results, neither fish oil nor aspirin can be recommended for prevention of AVF failure and additional strategies to reduce the high AVF failure rate are urgently required.